Publication:
Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Simple item page
dc.contributor.authorGÜMÜŞ, MAHMUT
dc.contributor.authorSezer, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.contributor.authorCicin, I.
dc.contributor.authorBentsion, D.
dc.contributor.authorGladkov, O.
dc.contributor.authorClingan, P.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorRizvi, N.
dc.contributor.authorMcginniss, J.
dc.contributor.authorPouliot, J.
dc.contributor.authorLee, S.
dc.contributor.authorSeebach, F.
dc.contributor.authorLowy, I.
dc.contributor.authorGullo, G.
dc.contributor.authorRietschel, P.
dc.date.accessioned2021-11-23T20:59:10Z
dc.date.available2021-11-23T20:59:10Z
dc.date.issued2021-10-01T00:00:00Z
dc.identifier.citationBondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29649
dc.identifier.wosWOS:000709606500217
dc.titleClinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
dc.typeArticle
dspace.entity.typePublication
local.avesis.id79ee8e48-2948-4265-ace9-152091eef525
local.publication.isinternational1
Files
Collections
Yayınlar - Eserler